[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-complications":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100583281","ocular-complications-from-cancer-therapy---patient-registry-and-biobank-100583281",false,"NCT06874283","Ocular Complications From Cancer Therapy - Patient Registry and Biobank","Registry and Biobank of Patients With a History of Cancer Therapy","Inclusion Criteria for the Cancer Therapy Group:\n\n* Adult patients (greater than 18 years of age)\n* Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery)\n* Patients who have a history of allogenic HSCT with all stem cell sources including bone marrow, PBSC, cord AND\u002FOR patients with a history of prior cancer therapy including BMT, chemotherapy, and immunotherapy\n* Patients will be recruited after their HSCT or cancer therapy at their ophthalmology appointment\n* Patients can be included with a history of prior cancer therapy including chemotherapy, BMT, immunotherapy. Prior cancer therapy must be identified and documented.\n* The patient must be able to understand and sign and date the informed consent form approved by the IRB.\n\nInclusion Criteria for the Control Group:\n\n* No history of cancer or cancer therapy in the past\n* Adult patients (greater than 18 years of age)\n* Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery)\n* The patient must be able to understand and sign and date the informed consent form approved by the IRB.\n\nExclusion Criteria for the Cancer Therapy Group:\n\n* Vulnerable populations: neonates, children, prisoners, institutionalized individuals\n* Inability or refusal to provide informed consent.\n* History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma).\n\nExclusion Criteria for the Control Group:\n\n* Vulnerable populations: neonates, children, prisoners, institutionalized individuals\n* Inability or refusal to provide informed consent.\n* History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma).\n* History of cancer or cancer therapy including chemotherapy, immunotherapy, BMT.",true,"ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect data on patients seen at University of Maryland after undergoing cancer therapy. Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and outcomes will be gathered on the patients who consent to participate. Potential subjects will be enrolled from the clinical practice of the investigator at the time of their eye examination visit. A standard of care exam will be performed pertinent to the reason for the visit. In addition to the standard of care exam, certain biological specimens (ocular surface wash, mucocellular material, corneal filaments, impression cytology, and\u002For blood) will be collected, stored, and analyzed to obtain immunologic, cellular, or molecular mechanistic insights into disease pathogenesis.",[25,26,27],"Graft Versus Host Disease in Eye","Ocular Complications","Inflammatory Dry Eye Disease",[29,30,31,32,33,34],"ocular graft versus host disease","allogenic stem cell transplant","blood cancer","ocular complications","inflammatory dry eye disease","ocular surface disease","RECRUITING","2026-03-03",{"date":38,"type":39},"2026-03-05","ACTUAL",{"date":41,"type":39},"2025-05-13",{"date":43,"type":21},"2031-04",{"name":45,"class":46},"University of Maryland, Baltimore","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":47},"100577806","the-impact-of-systemic-light-chain-amyloidosis-on-eyes-100577806","NCT06803082","The Impact of Systemic Light Chain Amyloidosis on Eyes","The Impact of Systemic Light Chain Amyloidosis on Eyes and Its Appendages","Amyloidosis","Case Group\n\nInclusion Criteria:\n\n1. Patients diagnosed with \"Systemic Light Chain Amyloidosis\";\n2. No other severe systemic underlying diseases that affect the examination;\n3. Subjects voluntarily participate in this study, sign the informed consent form;\n4. Age between 18-80 years old, no gender restrictions.\n\nExclusion Criteria:\n\n1. Patients with eye diseases of clear causes such as ocular surface malignant tumors, corneal perforation, severe eye trauma, etc.;\n2. Patients with nystagmus;\n3. Severe ocular scar diseases; conjunctival scars with fornix shortening;\n4. Current signs of infection, including fever and undergoing antibiotic treatment;\n5. Mental abnormalities;\n6. Pregnant or breastfeeding women, or women planning to become pregnant within 2 years;\n7. NYHA Class IV: Heart disease patients cannot engage in any physical activity, with heart failure symptoms even at rest, and worsening with physical activity;\n8. NT-proBNP \\> 8,500 ng\u002FL.\n\nControl Group\n\nInclusion Criteria:\n\n1. Stable general condition, not patients with \"Systemic Light Chain Amyloidosis\";\n2. No other severe systemic underlying diseases that affect the examination;\n3. Subjects voluntarily participate in this study, sign the informed consent form;\n4. Age between 18-80 years old, no gender restrictions.\n\nExclusion Criteria:\n\n1. Patients with eye diseases of clear causes such as ocular surface malignant tumors, corneal perforation, severe eye trauma, etc.;\n2. Patients with nystagmus;\n3. Severe ocular scar diseases; conjunctival scars with fornix shortening;\n4. Current signs of infection, including fever and undergoing antibiotic treatment;\n5. Mental abnormalities;\n6. Pregnant or breastfeeding women, or women planning to become pregnant within 2 years.","80 Years",{"count":58,"type":21},130,"Study Purpose and Principle: Amyloidosis is a group of diseases characterized by the deposition of amyloid proteins in tissues and organs throughout the body, with common affected organs including kidneys, heart, nervous system, gastrointestinal tract, and liver. Nowadays, nearly 40 different proteins have been found to form amyloid fibrils in body, among which Systemic Light Chain (AL) Amyloidosis is the most common type of systemic amyloidosis. AL amyloidosis is a plasma cell disorder, with its precursor protein originating from free light chains produced by abnormal plasma cell clones, which form amyloid substances that deposit in tissues and organs causing lesions. In terms of incidence, the incidence of AL amyloidosis is 8-10 cases per million person-years in the United States and is considered a rare disease in our country. AL amyloidosis has an insidious onset, diverse clinical manifestations, and is prone to misdiagnosis and missed diagnosis in clinical practice. The prognosis also has strong heterogeneity and is closely related to the extent of organ involvement at the time of diagnosis. In the past, the incidence of eye involvement in systemic AL amyloidosis patients was low, with various manifestations, only reported as case reports, and not regularly followed up with systemic treatment. Based on this, this project aims to assess the involvement of eyes and its appendages in patients with different stages of systemic light chain amyloidosis, with the goal of clarifying the ocular manifestations of this systemic disease and exploring early diagnostic indicators for the eye.\n\nPrimary Objective: To assess the involvement of the anterior segment of the eye, as well as the extraocular soft tissues and muscles, in patients with systemic light chain amyloidosis.\n\nSecondary Objective: To assess the neuro-ophthalmic manifestations and changes in retinal choroidal blood flow in patients with systemic light chain amyloidosis.\n\nStudy Design: Observational study.\n\nStudy Population and Expected Enrollment: 80 patients with systemic light chain amyloidosis, 50 normal controls.\n\nStudy Duration: Six months of follow-up after the last subject is diagnosed and enrolled.\n\nIntervention: Experimental Group: Patients with systemic light chain amyloidosis; Control Group: Subjects without systemic diseases.",[61,26],"Systemic Light Chain Amyloidosis",[61,26],"2025-01-26",{"date":65,"type":39},"2025-01-31",{"date":67,"type":39},"2024-09-04",{"date":69,"type":21},"2026-08-13",{"name":71,"class":46},"Zhongshan Ophthalmic Center, Sun Yat-sen University"]